

European Monitoring Centre for Drugs and Drug Addiction

EMCDDA-update HIV/HCV among people who inject drugs: situation and response

Dagmar Hedrich

The EU HIV/AIDS Civil Society Forum: 23-24 November 2015, Luxembourg

Latest European overview

- Multi-indicator based analysis
- Update on HIV, hepatitis and other injecting-related harms in Europe
- Stimulant injecting and new risk behaviours
- Prisons as risk settings
- Trends in harm reduction funding


Released in 09/2015






Estimates of the prevalence of injecting drug use

(rate per 1 000 population aged 15–64), 2007–14 data collection (last study available)




Prevalence of injection among clients entering treatment with opioid as their primary drug






HIV prevalence among injecting drug users – studies with national and subnational coverage 2013-2014




Health and social responses to drug use

Countries: health and social responses: Interactive maps Treatment profiles Harm reduction profiles



Significant level of drug treatment provision


More than half of the 1,3 million problem opioid users are in opioid substitution treatment





NB: Data displayed as point estimates and uncertainty intervals.


Variable levels of syringe provision





NB: Data displayed as point estimates and uncertainty intervals.

NSP-sites: geographical coverage and performance



Performance: Syringes per NSP client

Appendix 2


Risk assessment — supplementary table. Indicators of HIV notification trend, HIV and HCV prevalence estimates, transmission risk and prevention coverage in 30 European countries

Country	HIV-related indicators		Indicators of transmission risk		Intervention coverage indicators	
	HIV case trend (')	HIV prevalence trend	HCV prevalence increasing or high HCV prevalence	Injecting drug use prevalence increasing or high	Problem opioid users in substitution treatment (%) (*)	Syringes distributed by specialised programmes (per injecting drug user per year) (=)
Austria					60	
Belgium						23
Bulgaria						
Croatia					41	215
Cyprus					19	0
Czech Republic					34	145
Denmark						
Estonia						407
Finland						226
France					80	
Germany					46	
Greece					62	81
Hungary					24	76
Ireland					41	
Italy					56	
Latvia					4	27
Lithuania					11	
Luxembourg					65	101
Malta					54	
Netherlands					58	
Norway					>50	359
Poland					11	
Portugal Romania						
Slovakia					8	
Slovakia					47	
Spain					>50	226
Sweden					200	220
Turkey						
United Kingdom					45	
ennee kingeom						

None of the following risk factors identified: increase in HIV case reports or prevalence of HIV or HCV; increase in transmission risk; low intervention coverage.


Risk factors possibly present: HIV or HCV prevalence or transmission risk showing increase at subnational level or


HCV antibody prevalence among PWID 2012–13



Samples with national Samples with sub-ina


Trends in age structure of clients entering treatment by primary drug







Recent/on-going transmission: HCV antibody prevalence amongst recent PWID (<2 yrs)



Indication of likely recent contamination and on going transmission among PWID



PERSPECTIVES ON DRUGS **Hepatitis C treatment** for injecting drug users

Transmitted through the sharing of needles, syringes and other injecting equipment, hepatitis C is the most common infectious disease among people who inject drugs in Europe today. In this analysis, the EMCDDA looks at some of the positive advances in treating the disease, including a new generation of medicines.



Introduction

Last update: 04.06.2015

1. Analysis


"Transmitted through the sharing of needles, syringes and other injecting equipment, hepatitis C is the most common infectious disease among injecting drug users in Europe today.In this analysis, the EMCDDA looks at some of the positive advances in treating the disease, including a new generation of medicines.

2. Video

3. Facts and figures

Part of the 'Perspectives on drugs' (PODs) series, launched alongside the annual European Drug Report, these designedfor-the-web interactive analyses aim to provide deeper insights into a selection of important issues.





4. New medicines



Find out more





4. Current treatment and new medicines



Access to DAAs

Wiessing et al., 2015 (PlosOne): Systematic Review

- Level of chronic infection in anti-HCV positive drug users 53%-97% (Md 72%);
- HIV co-infection varied btw. 0%-70%;
- Proportion of diagnosed PWID entering HCV treatment 1-19% (Md 9,5%);
- High level of undiagnosed HCV infections among PWID (24%-76%, Md 49%).

"Data on epidemiology, care and disease burden among PWID in Europe are sparse, but suggest many undiagnosed infections and poor treatment uptake"



Harvoni is among the most expensive medicines

but

the size of the targeted population is huge

MOST EXPENSIVE DRUGS CURRENTLY BILLED THROUGH THE U.S. PHARMACY BENEFIT

MEDICATION	PRIMARY INDICATION	NUMBER OF Potential U.S. Patients	COST PER 30-day RX		
Ceprotin	Protein C deficiency	20	20		
Carbaglu	NAGS (enzyme) deficiency	20			
Erwinaze	E. coli-sensitive acute lymphoblastic leukemia	1,000	> \$70K		
NovoSeven RT	Hemophilia A & B with inhibitors	5,000			
Feiba NF	Hemophilia A & B with inhibitors	5,000	5,000		
Adagen	Adenosine deaminase (enzyme) deficiency in certain patients with SCID	50			
Mononine	Hemophilia B	4,000			
Naglazyme	Mucopolysaccharidosis VI (enzyme deficiency)	50	\$50K - \$70K		
Cinryze	Hereditary angioedema	8,000			
Berinert	Hereditary angioedema	8,000	\$40K - \$50K		
H.P. Acthar	Infantile spasms	9,000			
AlphaNine SD	Hemophilia B	4,000			
Harvoni	Hepatitis C, genotype 1	2,400,000			
Elaprase	Mucopolysaccharidosis II (enzyme deficiency)	50,000	\$30K - \$35K		
Myalept	Leptin deficiency in lipodystrophy	500			
Zavesca	Gaucher disease type 1	8,000			
Ravicti	Urea cycle disorders	1,500			
Kogenate FS	Hemophilia A	12,500			

Miller, S. (2014)

Miller, S. (23-10-2014b), 'Harvoni: Orphan Drug Pricing for a Non Orphan Drug', SPECIALTY MEDICATIONS ----

Purpose: collect data on prices charged in Europe to the new and the previous generation of medicines for HCV

Prefilled questionnaire

8 medicines

2 from the previous generation

•Telaprevir (Invico) and Boceprevir (Victrelis)

•6 from the new generation

•Sofosbuvir (Sovaldi), Simeprevir (Olysio), Declatasvir (Daklinza), Ledipasvir + Sofosbuvir (Harvoni), Ombitasvir + Paritaprevir + Ritonavir (Viekirax) and Desabuvir (Exviera)

Authorization date

Reference prices (exfactory and general public)

Period: Between May and July 2015 Process: Voluntary Sources: National Focal Points or National Pricing and Reimbursement Authorities

Results of survey on HCV medication pricing

Conducted May-July 2015 Replies from 21 countries "Reference prices"

Previous generation (data from 16 countries): Boceprevir: 12.843-26.188 € (24-week course)

Interferon-free (data from 12 countries): Sofosbuvir: 39.462-58.449€ (12-week course)



PWID likely to be a major if not the main risk group among those infected with HCV in Europe, but:

- Low level of testing,
- Many unaware of infection, delaying entry into effective treatment;
- Medication price high;
- Referral and treatment pathways unclear;
- Need to improve staff training & collaboration between clinical/hepatology and addiction services;
- Reinfection risk.



Women and Drugs, 24 November 2015, Lisbon

Women and drugs is the focus theme of today's "Reitox Extended Network meeting"

Knowledge sharing and debate with delegates from 43 European countries

http://www.emcdda.europa.eu/events/2015/women-and-drugs.

Twitter feed @emcdda_live #WomenAndDrug.

Commemorating the International Day for the Elimination of Violence against Women – 25 November 2015





European Monitoring Centre for Drugs and Drug Addiction

www.emcdda.europa.eu

Acknowledgements: Eleni Kalamara, Isabelle Giraudon, Claudia Costa Storti

dagmar.hedrich@emcdda.europa.eu

emcdda.europa.eu



- f facebook.com/emcdda
- youtube.com/emcddatube
- •• flickr.com/photos/emcdda